
Publisher's PDF, also known as Version of record
License (if available): CC BY-NC
Link to published version (if available): 10.1136/bmj.l5774

Link to publication record in Explore Bristol Research
PDF-document

This is the final published version of the article (version of record). It first appeared online via BMJ Publishing Group at https://www.bmj.com/content/367/bmj.l5774. Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research
General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/user-guides/explore-bristol-research/ebr-terms/
Blood markers for cancer

Jessica Watson NIHR doctoral research fellow¹, Luke Mounce research fellow², Sarah ER Bailey research fellow², Sharon L Cooper patient contributor², Willie Hamilton professor of primary care diagnostics²

¹Centre for Academic Primary Care, Bristol Medical School, University of Bristol, Bristol, UK; ²University of Exeter, Exeter, UK

A 61 year old man with a one month history of back pain visits his general practitioner (GP). He has hypertension, has never smoked, and reports fatigue for several months. The pain is keeping him awake at night. He has not lost weight. Clinical examination is normal. The differential diagnosis for this patient is wide, including potential malignant causes such as pancreatic, myeloma, and prostate cancer or metastatic disease.

Cancer can be difficult to identify if many of the common symptoms are non-specific and low risk, and even the most well known “alarm” symptoms have relatively low positive predictive values (PPVs) for underlying malignancy¹; for example, weight loss has a PPV for underlying malignancy of only 0-3.3%;² while rectal bleeding has a PPV of 2.2-15.8%.³ Cancer markers used in hospital settings, when applied to low risk primary care patients, have low positive predictive values and high false positive rates.⁴ Identifying patients whose non-specific symptoms may be caused by cancer, rather than benign disease, is therefore a challenge for primary care physicians.

While formal diagnosis usually happens in secondary care, the first suspicion of cancer generally occurs in primary care. Patients whose symptoms represent an approximate risk of cancer of ≥3% are recommended by the National Institute for Health and Care Excellence (NICE) for urgent investigation, often by referral.⁵ Those with estimated risk <3% may receive an initial panel of primary care investigations, or triage testing, to stratify risk. Triage tests can provide clues to help identify patients for referral, and crucially can point towards the site of an underlying malignancy. This is particularly useful when the patient’s vague symptoms could be caused by several different cancer types, and can guide decision making on any need for further investigation.

This article discusses blood tests to detect or stratify risk for possible cancer in primary care and presents evidence for their use in symptomatic patients. First we consider tests that are not specific for any one type of cancer but which may help primary care providers stratify risk of malignancy. Then we discuss specific markers for certain types of cancer. Blood tests that might be used for screening asymptomatic patients, tests for less common malignancies (eg, gastrin, prolactin) or for monitoring patients with known malignancies, are beyond the scope of this article.

What you need to know

- “Triage” blood tests in primary care, such as haemoglobin, platelets, serum calcium level, liver function tests, and inflammatory markers such as C reactive protein and erythrocyte sedimentation rate may provide “clues” to cancer in patients with non-specific symptoms
- Triage tests do not have the performance characteristics of rule-out tests
- Evidence supports the use of only a small number of specific cancer markers, such as CA125 and PSA, in primary care

What is the next investigation?

Non-specific blood tests or clues for cancer

Several non-specific tests, commonly used in primary care, can provide “clues” towards possible cancer. Tests with a PPV for cancer of >1%, including haemoglobin, platelet count, serum calcium, liver function tests, and inflammatory markers such as C reactive protein (CRP) and erythrocyte sedimentation rate...
(ESR), are summarised in fig 1 (infographic). Tests with PPVs <1% for certain underlying malignancies are reported in the same graphic. These blood tests should not be measured routinely but should be considered in patients with low risk, but not no risk symptoms, such as unexplained weight loss or persistent tiredness. Rarely, the full blood count may identify a haematological cancer, but most tests act in a bayesian fashion, whereby a “positive test” makes cancer a more likely explanation.

Although non-cancer diagnoses can also commonly cause abnormal test results, further investigations or referral to rule out malignancy may be warranted. Conversely, a “negative” test makes cancer less likely, though neither result is definitive; that is, if these test results are normal, cancer may still be present. None of these tests have sufficient sensitivity to act as a “rule out” test, with the possible exception of the combination of a normal plasma viscosity or ESR plus normal full blood count, which may be used as a simple rule out for myeloma. In the context of low risk symptoms, negative tests provide some reassurance. However, if symptoms continue or change, further investigation may still be warranted. Ideally, the rationale for and implications of a negative or positive test result should be discussed before ordering these tests so as to allow for shared decision making with patients.

Specific cancer markers

Despite the proliferation of cancer biomarker research in secondary care, there is a shortage of relevant primary care studies, with no new markers entering primary care usage since Sturgeon et al’s review in 2009.1 The small number of cancer specific tests validated for diagnosis of cancer in primary care settings are summarised in the infographic (fig 1). These tests should be used in symptomatic patients, rather than as a non-specific cancer screen. Even well known cancer markers that are part of routine clinical practice, such as prostate specific antigen (PSA) and cancer antigen 125 (CA125), have a limited primary care evidence base. In the case of PSA, because so many men who develop prostate cancer will be asymptomatic,12 positive predictive value of a positive test does not necessarily translate into clinical benefit.

Outcome

The general practitioner was concerned by the presence of night pain and fatigue, which, in combination with the patient’s age, raised the possibility of underlying malignancy. The patient was therefore referred for initial blood tests, which included a full blood count, liver function tests, serum calcium, and ESR. The test results were significant for a slightly raised platelet count (495x10^9/L) and a mildly raised ESR (34 mm/h). Further specific blood tests were therefore performed, including serum electrophoresis and Bence Jones protein. Monoclonal immunoglobulins were detected, suggestive of multiple myeloma. The patient was referred urgently to a suspected cancer clinic, where the diagnosis was confirmed.

Future research

Many cancer biomarkers are being investigated, particularly for cancers considered “hard to diagnose,” such as pancreas and ovary, or for early detection of cancer recurrences. However, of the candidate cancer biomarkers, few are expected to be tested for in clinical practice. Future research to evaluate markers for a potential diagnostic role should aim to quantify the false-positive rates, clinician and patient acceptability, and health economic aspects in order to determine how these tests should best be used.

How patients were involved in the creation of this article

A first patient contributor was involved in the early stages of the article but was unavailable during the main creation of the piece. SC joined at that stage, and has helped interpret our findings, especially the patient aspects, and in critical review of the whole manuscript, ensuring it remained patient centred.

Contributors

LM performed the searches, LM, SB, and WH reviewed abstracts and extracted full texts. JW, WH, and SB wrote the first draft of the article with input from LM and SC. All authors contributed to the intellectual content, edited the manuscript and approved the final version for submission.

Competing interests

The BMJ has judged that there are no disqualifying financial ties to commercial companies. The authors declare the following other interests:

Funding: The author WH is co-Principal Investigator of, and the author SERB is funded by, a Cancer Research UK Population Research Catalyst award (C8640/A23385). JW is funded by a Doctoral Research Fellow from the National Institute for Health Research (DRF-2016-09-034). LM is funded by The Policy Research Unit in Cancer Awareness, Screening and Early Diagnosis which receives funding for a research programme from the Department of Health Policy Research Programme. It is a collaboration between researchers from seven institutions (Queen Mary University of London, UCL, King’s College London, London School of Hygiene and Tropical Medicine, Hull York Medical School, Durham University and Exeter Medical School). WH is supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South West Peninsula at the Royal Devon and Exeter NHS Foundation Trust.

Further details of The BMJ policy on financial interests are here: https://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/declaration-competing-interests

The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

Patient consent not required (patient anonymised or hypothetical)

Provenance and peer review: commissioned, based on an idea from the author; externally peer reviewed.

4 Usher-Smith JA, Sharp SJ, Griffin SJ. The spectrum effect in tests for risk prediction, screening, and diagnosis. BMJ 2016;353:i3139. 10.1136/bmj.i3139 27334281
8 Sturgeon CM, Lai LC, Duffy MJ. Serum tumour markers: how to order and interpret them. BMJ 2009;339:b3027. 10.1136/bmj.b3027 19773328
13 Rhea JM, Molinaro RJ. Cancer biomarkers: surviving the journey from bench to bedside. MLO 2011;43:10-2, 16, 18, 20, 22.
English electronic medical records and cancer registry data. Br J Gen Pract
2017;67:e405-13. 10.3399/bjgp17X691109 2853199

16 Hamilton W, Peters TJ, Round A, Sharp D. What are the clinical features of lung cancer before the diagnosis is made? A population based case-control study. Thorax
2005;60:1059-65. 10.1136/thx.2005.045880 16227326

2014;111:1410-2. 10.1038/bjc.2014.433 25093495

2016;33:449-52. 10.1093/fampra/cmw051 27343860

10.1097/MPA.0000000000000527 26495795

20 Hamilton W. The CAPER studies: five case-control studies aimed at identifying and quantifying the risk of cancer in symptomatic primary care patients. Br J Cancer
2009;101(Suppl 2):S80-6. 10.1038/bjc.2009.432 19556169

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
**Figure**

Predictive values of diagnostic blood tests as non-specific cancer markers, based on primary care studies or reviews

**Fig 1** Primary care studies or review investigating the diagnostic role of blood tests as non-specific cancer markers: with positive predictive values (PPVs) ≥1% and <1%